The announcement from Merck & Co. and Moderna last month that their mRNA cancer vaccine had successfully lengthened patient ...

The FDA has delayed its approval decision for Exelixis’ oral kinase inhibitor zanzalintinib in combination with Roche’s ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. | ...

The 5-star Raffles Hotel in Boston was a fitting location for the launch of Singapore’s fifth international hub in the U.S., ...

MelliCell CEO Ben Pope, Ph.D., echoed the need for increased access to funds. The Greater Boston-based biotech company has a ...

Frazier Life Sciences (FLS) has stacked up another sizable biotech-focused capital commitment, netting more than $1.1 billion ...

The FDA has put enrollment in trials of Biohaven’s epilepsy drug candidate BHV-7000 on hold in response to findings from ...

Neuro-focused Encoded Therapeutics has bagged a $275 million series F round to support its Dravet syndrome asset and scale up ...

Tyra Biosciences has reported initial phase 2 data on dabogratinib in bladd | Tyra Biosciences has reported initial phase 2 ...

Andy Plump, M.D., Ph.D., president of research and development at Takeda, is set to leave the company in June. Plump joined the Japanese drugmaker in 2015, arriving from Sanofi to initially serve as ...

Evommune’s G-protein coupled receptor X2 (MRGPRX2) antagonist has flunked another phase 2 trial, wiping out the biotech’s ...